Massano, A.; Savarino, E.V.; Saibeni, S.; Bezzio, C.; Bertani, L.; Caviglia, G.P.; Vernero, M.; Armandi, A.; Ribaldone, D.G.
Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study. J. Clin. Med. 2025, 14, 1793.
https://doi.org/10.3390/jcm14061793
AMA Style
Massano A, Savarino EV, Saibeni S, Bezzio C, Bertani L, Caviglia GP, Vernero M, Armandi A, Ribaldone DG.
Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study. Journal of Clinical Medicine. 2025; 14(6):1793.
https://doi.org/10.3390/jcm14061793
Chicago/Turabian Style
Massano, Alessandro, Edoardo Vincenzo Savarino, Simone Saibeni, Cristina Bezzio, Lorenzo Bertani, Gian Paolo Caviglia, Marta Vernero, Angelo Armandi, and Davide Giuseppe Ribaldone.
2025. "Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study" Journal of Clinical Medicine 14, no. 6: 1793.
https://doi.org/10.3390/jcm14061793
APA Style
Massano, A., Savarino, E. V., Saibeni, S., Bezzio, C., Bertani, L., Caviglia, G. P., Vernero, M., Armandi, A., & Ribaldone, D. G.
(2025). Relapse Rates and Predictors for Relapse in Ulcerative Colitis and Crohn’s Disease Patients After Discontinuation of Vedolizumab or Ustekinumab: The REVEUS Study. Journal of Clinical Medicine, 14(6), 1793.
https://doi.org/10.3390/jcm14061793
